Extra ‘triple therapy’ drug for type 2 diabetes

NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. Dapagliflozin can be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

 Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs. This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.”

 

 

Other news

Upcoming Events

BSG Annual Meeting 2017

Manchester Central Convention Complex Ltd
19th - 23rd June 2017

BADS ASM 2017

Southport Convention Centre
22nd - 23rd June 2017

Health+Care 2017

ExCeL London
28th - 29th June 2017

The British Society of Audiology Annual Conference

Majestic Hotel, Harrogate
29th – 30th June 2017

Infection Prevention & Control 2017

Centenary Pavilion, Elland Road Stadium, Leeds
Wednesday 12th July 2017

Latest Issue

Clinical Services Journal

Clinical Services Journal

May 2017

The true value of point-of-care ultrasound

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.